By Product
-
Consumables
-
Instruments
-
Software and Services
By Technology
-
In Vitro Diagnostics
-
Imaging
-
Biopsy
-
Others
By Cancer Type
-
Breast Cancer
-
Lung Cancer
-
Colorectal Cancer
-
Prostate Cancer
-
Others
By End User
-
Hospitals and Clinics
-
Diagnostic Laboratories
-
Others
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Roche, Abbott, Thermo Fisher Scientific, Illumina, QIAGEN, Hologic, Siemens Healthineers, GE HealthCare, Guardant Health, Natera, GRAIL, Myriad Genetics, Agilent Technologies, Bio-Rad Laboratories, Danaher, Becton Dickinson, Sysmex and Philips.
Key opportunities include multi-cancer early detection, liquid biopsy and minimal residual disease testing, digital pathology with artificial intelligence, and affordable testing for emerging markets building screening programs.
Rising cancer incidence, expanding screening programs and the spread of precision oncology with companion diagnostics are the main growth factors, supported by falling sequencing costs.
By Product, the Consumables segment dominated the market in 2025 with an estimated 61.43% share, supported by recurring purchases of assay kits and reagents.
North America dominated the market with a share of 38.50% in 2025, driven by high screening rates, broad coverage and early adoption of molecular tests.